Amyloidosis

Midwest CEPAC

ICER reviewed new therapies for the treatment of hereditary transthyretin-related (hATTR) amyloidosis, a rare genetic condition characterized by nerve, heart, and eye damage that is currently treated through supportive measures alone. Therapies included inotersen (Akcea Therapeutics ), an antisense oligonucleotide that interferes with transthyretin production in the liver, and patisiran (OnpattroTM, Alnylam Pharmaceuticals), which inhibits transthyretin through an RNA interference pathway.

Associated Meetings

September 13, 2018 9am- 5pm CT

Chicago Marriott at Medical District/UIC

625 S Ashland Ave

Chicago, IL 60607

The Midwest CEPAC deliberated and voted on ICER's report on treatments for hereditary transthyretin-related (hATTR) amyloidosis, a rare genetic condition characterized by nerve, heart, and eye damage that is currently treated through supportive measures alone. The Council also reviewd a report on therapies for prostate cancer during this meeting.


Key Dates

Associated Materials

02/16/2018 – 03/07/2018
Open Input Period

03/12/2018

Open to public comment until April 2, 2018. Click here for more information on submitting a public comment, please visit our stakeholder engagement page.


03/12/2018

03/12/2018 – 04/02/2018